NCT00501124已完成4 期
Phase IV Study to Evaluate the Safety and Efficacy of Clevudine Compared With Clevudine and Vaccine in Patients Chronically Infected With HBV, HBeAg(+)
Bukwang Pharmaceutical10 个研究点 分布在 2 个国家目标入组 70 人开始时间: 2007年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 试验地点
- 10
- 主要终点
- Antiviral Activity: Proportion of patients with HBeAg loss
研究概览
简要总结
A randomized, parallel, multicenter, active-controlled with 48 weeks of treatment period. Patients will be randomized to receive clevudine alone for 48 weeks or clevudine for 24 weeks followed by 24 weeks of clevudine in addition to monthly HBV vaccination.The purpose of this study is to investigate efficacy of combination of clevudine and HBV vaccine over clevudine alone in patients with chronic hepatitis B infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is between 18 and 60
- •Patient is HBV DNA positive with DNA levels ≥ 5 x 10(6) copies/mL within 30 days of baseline.
- •Patient is documented to be HBsAg positive for > 6 months. Patient is HBeAg positive.
- •Patient has ALT levels which are in the range of ≥2 x ULN/L at least 2 consecutive visits, at least one month apart and bilirubin levels less than 2.0 mg/dL, prothrombin time of less than 1.7 (INR), a serum albumin level of at least 3.5 g/dL.
- •Women of childbearing potential must have a negative urine (β-HCG) pregnancy test taken within 14 days of starting therapy.
- •Patient is able to give written informed consent prior to study start and to comply with the study requirements.
排除标准
- •Patient is currently receiving antiviral, immunomodulatory, cytotoxic or corticosteroid therapy.
- •Patients previously treated with interferon, lamivudine, adefovir, entecavir, telbivudine or any other investigational nucleoside for HBV infection.
- •Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
- •Patient is coinfected with HCV, HDV or HIV.
- •Patient with clinical evidence of decompensated liver disease or HCC
- •ANA > 1:160 and positive anti-smooth muscle antibody as evidence of autoimmune hepatitis
- •Patient is pregnant or breast-feeding.
- •Patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases.
- •Patient has a clinically relevant history of abuse of alcohol or drugs.
- •Patient has a significant immunocompromised, gastrointestinal, renal, hematological, psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic GB stone, neurological, cardiac, oncologic or allergic disease or medical illness that in the investigator's opinion might interfere with therapy. The patient with a benign tumor, excluded if judged by an investigator that the continuation of study would be interfered by the tumor.
- •Patient has creatinine clearance less than 60mL/min as estimated by the following formula: (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]
结局指标
主要结局
Antiviral Activity: Proportion of patients with HBeAg loss
时间窗: Screening, Day1(predose), every 4 weeks during treatment period(48weeks)
Safety Endpoints:Laboratory tests, Adverse Events, Vital signs, ECG
时间窗: Screening, Day1(predose), every 4 weeks during treatment period(48weeks), ECG: screening, Week48
次要结局
- Proportion of patients with HBV DNA below LOD, Biochemical improvement, Proportion of patients with seroconversion(Screening, Day1(predose), every 4 weeks during treatment period(48weeks))
- Immunological endpoints: Alterations in immunological parameters before, after therapy, particularly with regards to the proliferative a(Day1(predose), Week 8, 16, 24, 28, 32, 40 and 48)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
4 期
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the KneeOsteoarthritis of KneeNCT02682524Daewon Pharmaceutical Co., Ltd.191
已完成
4 期
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic FailureHIV InfectionNCT00038506ViiV Healthcare100
已完成
4 期
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)Chronic Rhinosinusitis With Nasal PolypsNCT05049122Sanofi25
招募中
4 期
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.End Stage Renal Disease (ESRD)NCT06597201Chengdu Qingshan Likang Pharmaceutical Co., Ltd400
已完成
4 期
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver DiseasesType2 DiabetesNon-Alcoholic Fatty Liver DiseaseNCT03910361Dong-A ST Co., Ltd.51